Secukinumab as a Novel Treatment for Chronic Netherton Syndrome in a Young Adult

Irma Buchukuri; Giorgi Chalatashvili; Maia Gotua; Kakhaber Robakidze; Nino Khutsishvili; Nino Lortkipanidze

doi:10.12659/AJCR.946411

29 April 2025 : Case report Georgia

Secukinumab as a Novel Treatment for Chronic Netherton Syndrome in a Young Adult

Challenging differential diagnosis, Rare disease, Educational Purpose (only if useful for a systematic review or synthesis)

Irma Buchukuri

^{ABCDEF 1,2}, Giorgi Chalatashvili^{CDEF 2,3*}, Maia Gotua^{CDF 4}, Kakhaber Robakidze^{CDEF 5}, Nino Khutsishvili^{BCD 6,3}, Nino Lortkipanidze

^{BCD 6,3}

DOI: 10.12659/AJCR.946411

Am J Case Rep 2025; 26:e946411

Authors information Article notes Copyright and License information

Introduction Case Report Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Figure 4 Pictures of the patient after 2 injections of secukinumab. The patient demonstrated mild erythema without scales or plaques.

Back to the Article

Secukinumab as a Novel Treatment for Chronic Netherton Syndrome in a Young Adult

Your Privacy